pioglitazone

Pioglitazone (U 72107) 是一种 PPARγ激动剂，作用于人和鼠 PPARγ 的 EC50 分别为 0.93 和 0.99 μM，具有选择性、口服活性。Pioglitazone 可用于糖尿病研究。

Pioglitazone hydrochloride (AD 4833) 是一种选择性PPARγ激动剂，高亲和力结合到 PPARγ 配体结合域。作用于人和鼠 PPARγ，EC50分别为 0.93 和 0.99 μM。它是一种口服活性噻唑烷二酮的盐酸盐，具有抗糖尿病特性和潜在的抗肿瘤活性。

Pioglitazone D4 is a deuterium labeled Pioglitazone. Pioglitazone is a agonist of PPARγ .

Pioglitazone potassium (U 72107) is an orally active and selective agonist of peroxisome proliferator-activated receptor gamma (PPARγ). It demonstrates high affinity binding to the ligand-binding domain of PPARγ, with an EC50 of 0.93 μM and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone potassium has applications in diabetes research [2] [3] [4].

(R)-Pioglitazone ((+)-pioglitazone) 为吡格列酮的R-型异构体，是一种选择性过氧化物酶体增殖物激活受体 (PPARγ) 激动剂，通过口服具有活性，并且在PPARγ的配体结合域中显示出高度亲和力。(R)-Pioglitazone 主要用于研究阿尔茨海默病。

Hydroxy Pioglitazone M-IV-d4 是 Hydroxy Pioglitazone M-IV 的氘代化合物。

Keto Pioglitazone-d4 是 Keto Pioglitazone 的氘代化合物。Keto Pioglitazone 的 CAS 号为 146062-45-5。

Pioglitazone hydrochloride (Standard) 是 Pioglitazone hydrochloride 的标准品，适用于定量分析、质量控制及生化实验等相关研究。Pioglitazone hydrochloride (AD 4833) 是一种选择性PPARγ激动剂，高亲和力结合到 PPARγ 配体结合域。作用于人和鼠 PPARγ，EC50分别为 0.93 和 0.99 μM。它是一种口服活性噻唑烷二酮的盐酸盐，具有抗糖尿病特性和潜在的抗肿瘤活性。

DRX-065 is a stabilized and deuterated R-enantiomer of pioglitazone. DRX-065 has pharmacological properties desirable for the treatment of NASH (mitochondrial function modulation, non-steroidal anti-inflammatory effects, and glucose lowering effects) with

Ketopioglitazone is an active metabolite of pioglitazone.

Leriglitazone, a metabolite of pioglitazone, binds to the PPARγ C-terminal ligand-binding domain (Ki: 1.2 μM) and induces transcriptional efficacy of the PPARγ (EC50: 680 nM). Leriglitazone PioOH is a PPARγ agonist, stabilizes the PPARγ activation functio

PPARγ agonist19 (Compound 5e) 是一种PPARγ激动剂。它对COX-1的IC50为11.27 μM，对COX-2的IC50为0.05 μM。在大鼠半膈肌实验中，PPARγ agonist19 能提高葡萄糖摄取效果，优于吡格列酮。此外，PPARγ agonist19 在2型糖尿病大鼠模型中可降低高血糖和胰岛素抵抗，并保护肾脏免受代谢功能障碍引起的损害，且减少脂血损害。

Rivoglitazone, also known as CI-1037; CS-011; DE-101; R-119702; Rivo, is a peroxisome proliferator-activated receptor γ agonist (PARPγ agonist) potentially for the treatment of type 2 diabetes. Rivoglitazone has been shown, through small clinical studies,

Leriglitazone (Hydroxypioglitazone) hydrochloride，吡格列酮的代谢产物。Leriglitazone (Hydroxypioglitazone) hydrochloride 是PPARγ激动剂，通过稳定PPARγ(AF-2) 共激活剂结合表面和增强共激活剂结合能力，提供高转录效力。 Leriglitazone (Hydroxypioglitazone) hydrochloride 与 PPARγC (LBD) 结合，其Ki 值为 1.2 μM，诱导PPARγ(LBD) 转录效率，EC50为 680 nM。